DAHUA-TECHNOLOGY
31.8.2022 14:46:35 CEST | Business Wire | Press release
Dahua Technology, a world-leading video-centric smart IoT solution and service provider, officially released the Dahua DeepHub Pro Series at its online global launch. Equipped with ultra-low-latency writing, one-tap wireless screen sharing, built-in camera & microphone and other advanced AI functions, Dahua DeepHub delivers a flexible, multimedia approach to teaching and conferencing, providing participants with an immersive, interactive and content-rich experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005338/en/
Traditional methods of learning in classroom settings have several challenges, including poor interaction between students and teachers, and potentially poor visual clarity from some positions in the room. Dahua’s DeepHub interactive whiteboard is designed to provide a content-rich, interactive and stimulating learning experience in schools and colleges, consigning to history conventional whiteboards and other presenting platforms. (Photo: Business Wire)
“Dahua DeepHub combines Dahua's advantages in core technologies such as video, audio and high-definition video transmission to offer a complete range of smart interactive whiteboards. From entry-level Lite Series to high-end Pro Series, this product meets the growing digitalization and collaboration demands of both business and education customer groups in the modern-day IoT world,” said Josh Wang, Product Manager of Dahua DeepHub.
The online launch highlighted several features of Dahua DeepHub. For instance, it utilizes Zero Air Gap Technology on the screen to reduce parallax for clearer image display. Ink signal latency is also optimized, providing approximately 50 pages or 1,500 strokes of continuous writing.
To enhance visual output and operation, Dahua DeepHub utilizes powerful AI functions including Handwriting Recognition that can recognize intelligible handwritten texts and shapes, and Gesture Control to easily operate the device anywhere in the room. It can even automatically detect and focus on the current speaker for better interaction. Also, on-screen materials can be displayed onto other devices in the room and be edited in real-time through the Two-way Sharing function.
Dahua DeepHub also supports SIMS device management system, allowing IT personnel to fully grasp the operating status of the device. It has flagship smartphone-level chip equipped with 8 execution engine GPU to ensure image rendering capability, and an NPU that offers five tops computing power – another unprecedented feature in the industry.
Furthermore, it operates using a single Type C cable that can replace HDMI, audio and touchscreen cables, and can supply power to external devices. It supports fingerprint access control, AirPlay, Chromecast, Miracast, and Eshare wireless connections, as well as Android 11 and Windows 10 operating systems that can be flexibly switched.
The complete range of Dahua DeepHub Series marks a step forward towards Dahua's goal of empowering cities and enterprises with digital transformation through smart IoT technologies. With more models in the upcoming months, Dahua will continue to deliver better digital experience to global customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005338/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom